Last Updated: [9/11/25]

Statements in this investor presentation/deck that are not purely historical, including statements regarding intentions, hopes, beliefs, expectations, representations, projections, plans, or predictions of the future, are forward-looking statements within the meaning of the  Private  Securities  Litigation  Reform  Act of  1995  and are subject to the safe  harbor provisions of such Act.

Words such as, but not limited to “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “should,” “will,” and similar expressions are intended to identify such forward-looking statements. The absence of these words does not necessarily mean that a statement is not forward-looking.

It is important to note that the Company’s actual results could differ materially from those in any such forward-looking statements. The Company’s actual results, performance, or achievements could differ materially from the results expressed in, or implied by, these forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, FDA approval, risks and uncertainties associated with the effect of changing economic conditions, trends in the medical device arena, variations in the Company’s potential cash flow, market acceptance risks, and supply costs.

The Company cautions investors not to place undue reliance on the forward-looking statements contained in this website, which speak only as of the date they are made. Transdermal Specialties Global, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release, whether as a result of new information, future events, changes in assumptions or otherwise.